Section 4.

Ethical, Legal, Social, and Health System Impact

No evidence available.

Section 5.

Recommendation

Given that favipiravir is not locally registered, the HTAC assumed that it will be intended for compassionate use in the management and treatment of COVID-19. The HTAC deemed that compassionate use is acceptable as long as the following conditions are followed:

1. There is a reasonable basis for its use (e.g., early trials show promise, no other drug is available).
2. A valid informed consent shall be obtained from the patients or their legally appointed representatives. The process shall be free of undue influence and coercive presence and the risks are well described and understood.
3. The clinical data and course must follow a systematic protocol which shall be the basis of subsequent reports to the DOH and FDA as required.
4. The health providers involved shall exercise due diligence in furthering its use in a clinical trial when sufficient amount of medicines (needed in the clinical trial) will be provided by the donor.

It is also in this context that the **HTAC supports the decision of the Philippine government to join a multi-country clinical trial** for favipiravir.

For inquiries, you may contact the HTA Unit:

4th Floor Pharmaceutical Division, Philippine Blood Disease and Transfusion Center, Diliman, Quezon City | Health Regulation Team, Department of Health, San Lazaro Compound, Sta. Cruz Manila | hta.philippines@gmail.com | doh.gov.ph | 8-875-7734 loc. 260 or 258